Page 139 - 南京医科大学自然版
P. 139

第45卷第12期         戴  丽,左祥林,胡 君. 鞘氨醇⁃1⁃磷酸信号通路在微循环障碍相关性心脏疾病中的作用及
                 2025年12月               治疗潜力[J]. 南京医科大学学报(自然科学版),2025,45(12):1810-1822                  ·1821 ·


                    1551                                               Cell Death Discov,2023,9(1):380
               [52] GERGELY P,NUESSLEIN⁃HILDESHEIM B,GUERINI     [63]RAZA Z,SALEEM U,NAUREEN Z. Sphingosine 1⁃phos⁃
                    D,et al. The selective sphingosine 1⁃phosphate receptor  phate signaling in ischemia and reperfusion injury[J].
                    modulator BAF312 redirects lymphocyte distribution and  Prostaglandins Other Lipid Mediat,2020,149:106436
                    has species⁃specific effects on heart rate[J]. Br J Pharma⁃  [64] LI Q,CHEN B,ZENG C,et al. Differential activation of
                    col,2012,167(5):1035-1047                          receptors and signal pathways upon stimulation by different
               [53]VALIŠ M,ACHIRON A,HARTUNG H P,et al. The bene⁃      doses of sphingosine⁃1⁃phosphate in endothelial cells[J].
                    fits and risks of switching from fingolimod to siponimod  Exp Physiol,2015,100(1):95-107
                    for the treatment of relapsing ⁃ remitting and secondary  [65]FREJ C,ANDERSSON A,LARSSON B,et al. Quantifica⁃
                    progressive multiple sclerosis[J]. Drugs R D,2023,23  tion of sphingosine 1⁃phosphate by validated LC⁃MS/MS
                   (4):331-338                                         method revealing strong correlation with apolipoprotein M
               [54]CREE B A,ARNOLD D L,FOX R J,et al. Long⁃term        in plasma but not in serum due to platelet activation
                    efficacy and safety of siponimod in patients with secondary  during blood coagulation[J]. Anal Bioanal Chem,2015,
                    progressive multiple sclerosis:analysis of EXPAND core  407(28):8533-8542
                    and extension data up to >5 years[J]. Mult Scler,2022,  [66]HE W S,CUI J Y,WANG X Y,et al. Early⁃stage pancre⁃
                    28(10):1591-1605                                   atic cancer diagnosis:serum biomarkers and the potential
               [55]SCOTT F L,CLEMONS B,BROOKS J,et al. Ozanimod        for aptamer ⁃ based biosensors[J]. Molecules,2025,30
                   (RPC1063)is a potent sphingosine⁃1⁃phosphate receptor⁃  (9):2012
                    1(S1P1)and receptor⁃5(S1P5)agonist with autoimmune  [67] LI S,SHEN Q L,ZHANG S H. Spatial transcriptomics⁃
                    disease⁃modifying activity[J]. Br J Pharmacol,2016,173  aided localization for single ⁃ cell transcriptomics with
                   (11):1778-1792                                      STALocator[J]. Cell Syst,2025,16(2):101195
               [56] COHEN J A,COMI G,SELMAJ K W,et al. Safety and  [68]NGUYEN Q,TUNG L W,LIN B,et al. Spatial transcrip⁃
                     efficacy of ozanimod versus interferon beta⁃1a in relapsing  tomics in human cardiac tissue[J]. Int J Mol Sci,2025,26
                     multiple sclerosis(RADIANCE):a multicentre,ran⁃  (3):995
                     domised,24 ⁃ month,phase 3 trial[J]. Lancet Neurol,  [69]XU Z M,IKUTA T,KAWAKAMI K,et al. Structural basis
                     2019,18(11):1021-1033                             of sphingosine ⁃ 1 ⁃ phosphate receptor 1 activation and
               [57] LOTT D,LEHR T,DINGEMANSE J,et al. Modeling         biased agonism[J]. Nat Chem Biol,2022,18(3):281-
                     tolerance development for the effect on heart rate of the  288
                     selective S1P1 receptor modulator ponesimod[J]. Clin  [70]MAEDA S,SHIIMURA Y,ASADA H,et al. Endogenous
                     Pharmacol Ther,2018,103(6):1083-1092              agonist⁃bound S1PR3 structure reveals determinants of G
               [58] SANDBORN W J,VERMEIRE S,PEYRIN⁃BIROULET            protein⁃subtype bias[J]. Sci Adv,2021,7(24):eabf5325
                    L,et al. Etrasimod as induction and maintenance therapy  [71] TOYOMOTO M,INOUE A,IIDA K,et al. S1PR3⁃G12⁃
                    for ulcerative colitis(ELEVATE):two randomised,double⁃  biased agonist ALESIA targets cancer metabolism and
                    blind,placebo ⁃ controlled,phase 3 studies[J]. Lancet,  promotes glucose starvation[J]. Cell Chem Biol,2021,28
                    2023,401(10383):1159-1171                         (8):1132-1144
               [59]WU X K,XU J W,LI X Y,et al. Inhibition of SphK1/S1P  [72]GAIDAROV I,KOMORI H K,STEPNIAK D T,et al.
                    signaling pathway alleviates fibrosis and inflammation of  Unique pharmacological properties of etrasimod among
                    rat myocardium after myocardial infarction[J]. Comput  S1P receptor modulators[J]. FEBS Open Bio,2025,15
                    Math Methods Med,2022,2022:5985375                (1):108-121
               [60]ZHANG F Y,XIA Y L,YAN W J,et al. Sphingosine 1⁃  [73]CASTRO R,ADAIR J H,MASTRO A M,et al. VCAM⁃1⁃
                    phosphate signaling contributes to cardiac inflammation,  targeted nanoparticles to diagnose,monitor and treat
                    dysfunction,and remodeling following myocardial infarc⁃  atherosclerosis[J]. Nanomedicine(Lond),2024,19(8):
                    tion[J]. Am J Physiol Heart Circ Physiol,2016,310(2):  723-735

                    H250-H261                                    [74] LV X F,ZHANG C,SHUAIZHEN Q Y,et al. Design of
               [61] SANTOS W L ,LYNCH K R. Drugging sphingosine        integrin αvβ3 targeting self⁃assembled protein nanoparti⁃
                     kinases[J]. ACS Chem Biol,2015,10(1):225-233      cles with RGD peptide[J]. Biomed Pharmacother,2020,
               [62]XIAO S Q,PENG K X,LI C X,et al. The role of sphingo⁃  128:110236
                    sine⁃1⁃phosphate in autophagy and related disorders[J].  [75] WILLIAMS P A,CAMPBELL K T,GHARAVIRAM H,
   134   135   136   137   138   139   140   141   142   143   144